<i>CYP2C19</i> Phenotype, P2Y<sub>12</sub> Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.

J Am Heart Assoc · 2025 · PMC12533675 · PMID 40611487

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

There was also a strong trend toward MAE rates being higher in the clopidogrel‐treated IM/PM group compared with the clopidogrel‐treated NM/RM/UM group (Figure 1D and Table 4 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

&lt;i&gt;CYP2C19&lt;/i&gt; Phenotype, P2Y&lt;sub&gt;12&lt;/sub&gt; Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.

The sentences

<i>CYP2C19</i> Phenotype, P2Y<sub>12</sub> Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.